<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03969485</url>
  </required_header>
  <id_info>
    <org_study_id>HALOCIP002</org_study_id>
    <nct_id>NCT03969485</nct_id>
  </id_info>
  <brief_title>Hybrid Fractional Laser for Treatment of Off Face Body Skin Quality</brief_title>
  <official_title>Non-Randomized, Open-label, Blinded Evaluator Study Characterizing Effectiveness of Hybrid Fractional Laser for the Treatment of Off Face Body Skin Quality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sciton</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sciton</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate effectiveness of hybrid fractional laser for the treatment of poor skin
      quality on the decolletage, back of the hands and lower legs
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Photography</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluate improvement in photography using Physicians Global Assessment Scale (0-4) where 0 is no change and 4 is very significant improvement.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">11</enrollment>
  <condition>Skin Laxity</condition>
  <arm_group>
    <arm_group_label>Hybrid Fractional Laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hybrid Fractional Laser Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hybrid Fractional Laser</intervention_name>
    <description>Hybrid Fractional Laser Device</description>
    <arm_group_label>Hybrid Fractional Laser</arm_group_label>
    <other_name>HALO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male/female subjects between 40 to 65 years of age inclusive

          2. Fitzpatrick skin type I-III

          3. Non-smokers or have not smoked (including vaping) within the past 14 days from the
             screening visit

          4. Has poor skin texture

          5. Has mild thin skin

          6. Has some level of dyschromia on the treatment area as assessed by the Investigator

          7. Can read, understand and sign informed consent form (English only)

          8. Has indicated willingness to participate in the study by signing an informed consent
             form

          9. Agrees to adhere to the treatment and follow-up schedule and post treatment care
             instructions

        Exclusion Criteria:

          1. Fitzpatrick skin type IV-VI

          2. Has tanned within the past 30 days or is unable or unlikely to refrain from tanning,
             including the use of tanning booths, tanning spray or cream

          3. Has tattoos, dysplastic nevi on the treatment area

          4. Is pregnant and/or lactating

          5. History or current photosensitivity

          6. History or current use of medication with photosensitizing properties within past 6
             months

          7. History or current of chronic reoccurring skin disease or disorder affecting treatment
             area

          8. History or current cancer of any type

          9. Has signs of actinic bronzing

         10. Has open lacerations, and abrasions on the treatment area

         11. History of keloid formation, or hypertrophic scar formation, or poor wound healing

         12. History of bleeding disorder, or is currently taking anticoagulation medications

         13. Has significant concurrent illnesses (controlled or uncontrolled), such as diabetes,
             lupus, epilepsy, or cardiac disorders, which might be aggravated as a result of
             treatment

         14. Has participated in any clinical trial involving an investigational drug, device or
             cosmetic product or procedure within the past 30 days

         15. The investigator feels that for any reason the subject is not eligible to participate
             in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sciton Inc</last_name>
    <phone>650-493-9155</phone>
    <email>clinicaltrials@sciton.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jay Patel</last_name>
    <phone>650-493-9155</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New Jersey Clinical Research Center</name>
      <address>
        <city>Montclair</city>
        <state>New Jersey</state>
        <zip>07042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>973-250-2996</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2019</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cutis Laxa</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

